Weekly Chart for ABUSIt seems ABUS is preparing for a big move. Weekly Chart is strong, over the 200w,100w and 50w MAV
−0.44USD
−72.85 MUSD
18.14 MUSD
136.99 M
About Arbutus Biopharma Corporation
Sector
CEO
Michael J. McElhaugh
Headquarters
Warminster
Website
Employees (FY)
73
Founded
2005
ISIN
CA03879J1003
FIGI
BBG000RR8V85
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
ABUS - Breakout AttemptAttempting to breakout of a large down channel
Price has already moved out of it.
Bars pattern placed shows my thoughts of a spike out of the down channel and the bulls taking control.
If this does not occur assume bear control still in play.
POTENTIAL BULLISHPrice is currently squeezing, with a 50/50 chance of breaking above or below. So, all we have to do now is wait for a bullish candle to appear and break above USD4.50 with strong bullish momentum as a final confirmation.
ABUS - Similarities to Prior RunIn this post various similarities are displayed, corresponding to the same color
Both double bottoms on 1.618 (in yellow)
Both tops at 1.618 (in red)
The positioning above the 200 day moving average as of current is also an extremely bullish sign
ABUS about to go up due to Patent on MRNA... Interesting... Lets hope there is news release.. I don't know for certain if its only the patent news but I am confident on my TA. DO your own DD!
short analysisBecause of the convergence we see in the chart and the RSI, and the gray support range that indicates the fall to that range has not been seen, we will probably see that the chart experiences some re-fall. If the pull back up, we will have price growth up to the gray resistance range. And God knows
#ABUS to 4.91 Climbing to New Target by 16%Sector: Health Technology
Industry: Biotechnology
Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warmins
ABUS - LongABUS CMP - $4.38
Looking bullish in higher time frame. One can go for Positional Trade Setup with the following entry, exit & targets.
Buy Range $3.90 - $4 ONLY / Stop Loss $2.95
Target 1 - $5
Target 2 - $7
Target 3 - $9
Disclaimer: This is my view and for educational purpose only.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ABUS is 2.97 USD — it has increased by 2.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arbutus Biopharma Corporation stocks are traded under the ticker ABUS.
Arbutus Biopharma Corporation is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Arbutus Biopharma Corporation has a max estimate of 5.00 USD and a min estimate of 4.00 USD.
ABUS earnings for the last quarter are −0.12 USD whereas the estimation was −0.11 USD which accounts for −7.14% surprise. Estimated earnings for the next quarter are −0.12 USD. See more details about Arbutus Biopharma Corporation earnings.
Arbutus Biopharma Corporation revenue for the last quarter amounts to 4.66 M USD despite the estimated figure of 4.75 M USD. In the next quarter revenue is expected to reach 4.78 M USD.
Yes, you can track Arbutus Biopharma Corporation financials in yearly and quarterly reports right on TradingView.
Like other stocks, ABUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arbutus Biopharma Corporation stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 73.00 employees. See our rating of the largest employees — is Arbutus Biopharma Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arbutus Biopharma Corporation EBITDA is −76.63 M USD, and current EBITDA margin is −422.41%. See more stats in Arbutus Biopharma Corporation financial statements.